全文获取类型
收费全文 | 3410篇 |
免费 | 416篇 |
国内免费 | 76篇 |
专业分类
耳鼻咽喉 | 117篇 |
儿科学 | 185篇 |
妇产科学 | 164篇 |
基础医学 | 332篇 |
口腔科学 | 67篇 |
临床医学 | 318篇 |
内科学 | 601篇 |
皮肤病学 | 104篇 |
神经病学 | 84篇 |
特种医学 | 91篇 |
外国民族医学 | 3篇 |
外科学 | 587篇 |
综合类 | 224篇 |
预防医学 | 73篇 |
眼科学 | 43篇 |
药学 | 92篇 |
中国医学 | 27篇 |
肿瘤学 | 790篇 |
出版年
2023年 | 67篇 |
2022年 | 82篇 |
2021年 | 163篇 |
2020年 | 162篇 |
2019年 | 172篇 |
2018年 | 141篇 |
2017年 | 164篇 |
2016年 | 166篇 |
2015年 | 159篇 |
2014年 | 196篇 |
2013年 | 243篇 |
2012年 | 167篇 |
2011年 | 156篇 |
2010年 | 145篇 |
2009年 | 144篇 |
2008年 | 151篇 |
2007年 | 166篇 |
2006年 | 152篇 |
2005年 | 124篇 |
2004年 | 118篇 |
2003年 | 90篇 |
2002年 | 63篇 |
2001年 | 70篇 |
2000年 | 52篇 |
1999年 | 47篇 |
1998年 | 60篇 |
1997年 | 51篇 |
1996年 | 38篇 |
1995年 | 43篇 |
1994年 | 28篇 |
1993年 | 32篇 |
1992年 | 28篇 |
1991年 | 33篇 |
1990年 | 21篇 |
1989年 | 23篇 |
1988年 | 23篇 |
1987年 | 16篇 |
1986年 | 27篇 |
1985年 | 20篇 |
1984年 | 15篇 |
1983年 | 12篇 |
1982年 | 11篇 |
1981年 | 21篇 |
1980年 | 12篇 |
1979年 | 10篇 |
1978年 | 4篇 |
1977年 | 9篇 |
1974年 | 1篇 |
1972年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有3902条查询结果,搜索用时 15 毫秒
1.
2.
3.
目的分析成人血液系统恶性肿瘤患者接受强烈化疗后中性粒细胞减少性肠炎(NE)的发生率、危险因素及预后情况。方法收集2004至2013年接受化疗的1804例血液系统恶性肿瘤患者,记录患者血常规、凝血检测和血液生化检测结果,并记录患者年龄、性别、原发病、既往化疗次数、既往化疗方案中是否使用阿糖胞苷、临床症状、肠壁厚度、中性粒细胞最低计数、中性粒细胞缺乏持续时间、NE的治疗方法和预后等,探讨NE起病诱因、临床特征、腹部B超特点、症状的预后意义及化疗药物对发病的影响等。结果1804例患者中226例(12.5%)化疗后合并NE,化疗后10~19d起病,中位起病时间为化疗后第14天。发生NE后26例患者死亡,病死率11.5%。化疗药物包括阿糖胞苷、临床症状≥4项、中性粒细胞缺乏持续超过7d以及B超下肠壁厚度≥10mm的患者病死率相对较高。结论NE是接受强烈化疗的血液系统肿瘤患者的严重的并发症,发生NE后患者病死率较高。 相似文献
4.
Gynecologic Malignancy-Associated Venous Thromboembolism and Predictive Tool at Thammasat University Hospital 下载免费PDF全文
Karit JayasakoonAwassada PunyashthiraBanthisa SomboonJunya PattaraarchachaiKomsun Suwannarurk 《Asian Pacific journal of cancer prevention》2022,23(6):2113-2118
Objectives: Aims were to investigate the prevalence and risk factors of venous thromboembolism (VTE) in gynecologic malignancy cases. Value of screening tool (Caprini) for prediction of VTE was also assessed. Study design: A retrospective study of gynecologic malignancy subjects who underwent major gynecological operation via exploratory laparotomy at Thammasat University Hospital, Pathum Thani, Thailand from January 2015 to December 2020. Participants were categorized into VTE and non-VTE groups. Caprini score, associated laboratory and clinical factors of both groups were evaluated. Results: A total of 392 subjects were recruited into the study. Prevalence of VTE was 7.4 (29/392) percent. VTE was diagnosed in subjects with endometrial, ovarian and cervical cancer at percentage of 7.8 (15/192), 7.9 (11/138) and 5.7 (3/53), respectively. Demographic characters of both groups were comparable. VTE group had significant more Caprini score, platelets count and platelet lymphocyte ratio (PLR) than non-VTE group. Modified Caprini score (2 multiply Caprini score plus 1 multiply PLR) was generated for better VTE prediction. Sensitivity and specificity of Caprini (≥5.5) and modified Caprini scores (≥22.8) were 72.4 vs 39.4, and 79.3 vs 52.1 percent, respectively. Conclusion: Prevalence of VTE among gynecologic malignancy cases was 7.4 percent. The modified Caprini score was an alternative VTE predictive tool. Cut-off point of modified Caprini score at equal or more than 22.8 was proposed. 相似文献
5.
Marcelo Sato‐Sano Solange Pistori Teixeira Juliano Cordova Vargas Otvio Cesar Carvalho Guimares Baiocchi Milvia Maria Simes e Silva Enokihara Elimar Elias Gomes Mariana Dias Batista 《The Journal of dermatology》2019,46(7):618-621
Eosinophilic dermatosis of hematological malignancy is a paraneoplastic skin eruption associated with chronic lymphocytic leukemia and other B‐cell malignancies. It clinically resembles an insect bite reaction and it can precede the symptoms of the hematological malignancy or be related to a more aggressive course. Different treatments have been proposed, but partial response and recurrence are frequent. Herein, we describe a case of eosinophilic dermatosis associated with mantle cell lymphoma with remission after lenalidomide therapy. 相似文献
6.
7.
《Clinical colorectal cancer》2020,19(4):277-284
BackgroundColorectal cancer (CRC) treatment for patients with peritoneal metastases is complex. The use of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has continued to be debated. The aim of the present study was to assess the consensus among international experts for decision-making regarding the use of CRS and HIPEC for patients with CRC.Materials and MethodsOf 15 experts invited, 12 had provided their decision algorithms for CRS and HIPEC for patients with, or at high risk of, peritoneal metastases from CRC. Using the objective consensus method, the results were transformed into decision trees to provide information on the consensus and discordance.ResultsOnly 1 scenario was found for which the consensus on performing HIPEC had reached 100%. The scenario was the treatment of young patients with complete cytoreduction and a peritoneal carcinomatosis index (PCI) of < 16 in the presence of certain risk factors. Five major decision criteria were identified: age, PCI, completeness of cytoreduction, extent of extraperitoneal metastases (EoMs), and, in the case of unverified EoMs, additional risk factors. Consensus was found regarding refraining from using HIPEC for older patients with a high PCI. The consensus further increased when addressing incomplete cytoreduction and an extensive extent of EoMs.ConclusionA definite consensus concerning the use of HIPEC was only determined for very selected scenarios. These findings can be used for general guidance; however, owing to the heterogeneity of each individual situation, the impracticality of presenting the information through decision trees, and the unclear future of the role of HIPEC in the adjuvant setting, a one-on-one transfer to daily clinical practice could not be achieved. 相似文献
8.
《Obstetrics, Gynaecology and Reproductive Medicine》2020,30(10):303-308
Cancer is rarely diagnosed during pregnancy, but the incidence of cases is increasing. Diagnosis may be delayed due to an assumption that symptoms are pregnancy-related, or a reluctance to perform investigations. Multidisciplinary discussion is vital, with decision-making involving the obstetrician, patient and family. Many cancers can be treated during pregnancy. Surgery is considered safe and chemotherapy after the first trimester does not increase fetal risks. Timing and mode of delivery will depend on the treatment plans as well as obstetric considerations. The rate of preterm birth is increased, but overall neonatal and paediatric outcomes do not seem to be affected. 相似文献
9.
Maggie L. Westfal David C. Chang Cassandra M. Kelleher 《Journal of pediatric surgery》2019,54(1):140-144
Purpose
The purpose of this study was to evaluate trends in demographics and outcomes of pediatric breast cancer in a United States population-based cohort.Methods
The Surveillance, Epidemiology, and End Results (SEER) database was utilized to identify all pediatric patients with malignant breast tumors between 1973 and 2014. Analysis was performed using Stata Statistical Software version 13.1. Associations between categorical variables were made using X2 test. Log-rank test was used for univariate survival analysis. Kaplan–Meier analysis investigated five-year survival rates across several variables. Adjusted analysis was performed using a Cox Proportional-Hazards regression.Results
134 patients with breast malignancies were identified. Carcinoma was the most prevalent histology (48.5%), followed by fibroepithelial tumors (FETs) (35.1%), and sarcoma (14.2%). FETs were twice as common in black compared to nonblack patients (56.3% vs. 29.0%, p?<?0.01). Analyzing histology by stage revealed that 100% of FETs were early stage disease (p?<?0.0001). 46.7% of the tumors tested were ER/PR negative, more than twice as many compared to the published adult estimate of 20.0%. Unadjusted survival analysis revealed worse survival for patients with adenocarcinoma/sarcomas, advanced stage, and high grade disease, without a survival difference between races.Conclusion
Breast cancer remains a rare malignancy among pediatric patients. Although black patients were found to have more noncarcinomatous tumors with less advanced disease, this did not confer a survival advantage.Type of study
Retrospective cohort study.Level of evidence
Level III. 相似文献10.
Naohiro Sekiguchi Shinya Rai Wataru Munakata Kenshi Suzuki Hiroshi Handa Hirohiko Shibayama Tomoyuki Endo Yasuhito Terui Noriko Iwaki Noriko Fukuhara Hiro Tatetsu Shinsuke Iida Takayuki Ishikawa Ryota Shiibashi Koji Izutsu 《Cancer science》2020,111(9):3327-3337
Tirabrutinib is a second‐generation Bruton’s tyrosine kinase inhibitor with greater selectivity than ibrutinib. Here, we conducted a multicenter, phase II study of tirabrutinib in patients with treatment‐naïve (Cohort A) or with relapsed/refractory (Cohort B) Waldenström’s macroglobulinemia (WM). Patients were treated with tirabrutinib 480 mg once daily. The primary endpoint was major response rate (MRR; ≥ partial response). Secondary endpoints included overall response rate (ORR; ≥ minor response), time to major response (TTMR), progression‐free survival (PFS), overall survival (OS), and safety. In total, 27 patients (18 in Cohort A; 9 in Cohort B) were enrolled. The median age was 71 y, and the median serum immunoglobulin M level was 3600 mg/dL. Among the patients, 96.2% had the MYD88L265P mutation. MRR and ORR were 88.9% and 96.3%, respectively (Cohort A: MRR, 88.9%; ORR, 94.4%; Cohort B: MRR, 88.9%; ORR, 100%). Median TTMR was 1.87 mo. PFS and OS were not reached with a median follow‐up of 6.5 and 8.3 mo for Cohorts A and B, respectively. The most common adverse events (AEs) were rash (44.4%), neutropenia (25.9%), and leukopenia (22.2%), with most AEs classified as grade 1 or 2. Grade ≥ 3 AEs included neutropenia (11.1%), lymphopenia (11.1%), and leukopenia (7.4%). No grade 5 AEs were noted. All bleeding events were grade 1; none were associated with drug‐related atrial fibrillation or hypertension. Although the follow‐up duration was relatively short, the study met the primary endpoint. Therefore, tirabrutinib monotherapy is considered to be highly effective for both untreated and relapsed/refractory WM with a manageable safety profile. (JapicCTI‐173646). 相似文献